Rilpivirine resistance and the dangerous liaisons with substitutions at position 184 among patients infected with HIV-1: Analysis from a national drug-resistance database (ARCA)-Reference-Cited by-同舟云学术

Rilpivirine resistance and the dangerous liaisons with substitutions at position 184 among patients infected with HIV-1: Analysis from a national drug-resistance database (ARCA)

Published:2014-05-17 Issue:9 Volume:86 Page:1459-1466
ISSN:0146-6615
Container-title:Journal of Medical Virology
language:en
Short-container-title:J. Med. Virol.

Author:

Rossotti Roberto¹,Fonte Luigi²,Meini Genny³,Maggiolo Franco⁴,Zazzi Maurizio³,Rusconi Stefano⁵,

Affiliation:

1. Department of Infectious Diseases; “Niguarda Cà Granda” Hospital; Milan Italy

2. Direzione Medica di Presidio; AO “A. Manzoni”; Lecco Italy

3. Section of Microbiology, Department of Molecular Biology; University of Siena; Siena Italy

4. Division of Infectious Diseases; “Giovanni XXIII” Hospital; Bergamo Italy

5. Clinic of Infectious Diseases, Department of Biomedical and Clinical Sciences “Luigi Sacco”; University of Milan; Milan Italy

Publisher

Wiley

Subject

Infectious Diseases,Virology

Reference29 articles.

1. Rilpivirine resistance mutations in HIV patients failing non-nucleoside reverse transcriptase inhibitor-based therapies;Anta;AIDS,2013

2. Cross-resistance among nonnucleoside reverse transcriptase inhibitors limits recycling efavirenz after nevirapine failure;Antinori;AIDS Res Hum Retroviruses,2002

3. Prevalence of transmitted HIV-1-infected patients in Italy: Evolution over 12 years and predictors;Bracciale;J Antimicrob Chemother,2009

4. Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): A phase 3, randomised, non-inferiority trial;Cohen;Lancet,2011

5. Efficacy and safety of Rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naïve HIV-1-infected patients: Pooled results from the Phase 3 double-blind randomized ECHO and THRIVE trials;Cohen;J Acquir Immune Defic Syndr,2012

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prevalence of rilpivirine resistance in people starting antiretroviral treatment in Argentina;Antiviral Therapy;2017

2. Factors influencing the efficacy of rilpivirine in HIV-1 subtype C in low- and middle-income countries;Journal of Antimicrobial Chemotherapy;2015-10-30